Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference
Rhea-AI Summary
Aptorum Group (NASDAQ: APM) and DiamiR Biosciences announced three scientific presentations at the 2026 Alzheimer’s Association International Conference (AAIC) in London and online, July 11-15, 2026.
Presentations cover plasma-based APOE genotyping, blood microRNA biomarkers for Alzheimer’s progression, and automated APOE genotyping for point-of-care use.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 22 | Alzheimer’s collaboration | Positive | +4.6% | Collaboration to generate blood-based Alzheimer’s biomarker data using DiamiR platforms. |
| Jun 10 | Merger approval | Neutral | -19.3% | Shareholder approvals for all-stock merger making DiamiR a wholly owned subsidiary. |
| Mar 10 | Biomarker study publication | Positive | -0.9% | Publication of microRNA-based glioblastoma biomarker study showing blood test feasibility. |
| Mar 06 | Nasdaq deficiency notice | Negative | +0.0% | Notification of non-compliance with Nasdaq $1 minimum bid price and 180-day cure window. |
| Feb 02 | APOE platform collaboration | Positive | -10.2% | Collaboration to validate INB’s automated APOE testing platform in DiamiR’s clinical lab. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Over recent months the stock has often traded flat-to-down on operational or transaction news, with only one collaboration headline seeing a clearly positive next-day reaction.
Regulatory & Risk Context
Reported short positioning appears relatively low, indicating limited short-squeeze potential and suggesting that forced covering is unlikely to be a major driver of volatility.
An effective mixed shelf registration for up to $75,000,000 of securities, plus additional resale-registered warrants, gives the company flexibility to raise capital over time, which can introduce potential dilution and resale overhang for existing holders.
Key Terms
clia-certified technical
cap-accredited technical
apoe genotyping medical
microRNAs medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, July 08, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced upcoming presentations at the annual Alzheimer’s Association International Conference (AAIC), taking place at the Excel London Convention & Exhibition Centre, in London, UK, and online, on July 11-15, 2026, showcasing biomarker technologies from DiamiR’s CLIA-certified, CAP-accredited clinical laboratory.
Alidad Mireskandari, Ph.D., Chief Executive Officer of DiamiR, will make the following presentations:
Abstract Title: Plasma-based APOE Genotyping: Development and Optimization of A Robust Protocol
Poster Number: 1160
Session Title: Developing Topics: Biomarkers
Date and Time: Sunday, July 12, 2026, 7:30 AM to 4:15 PM BST
Abstract Title: Circulating Brain-enriched And Inflammatory MicroRNAs As Blood Biomarkers Of Mild Cognitive Impairment To Alzheimer's Progression
Poster Number: 1037
Session Title: Developing Topics: Biomarkers
Date and Time: Sunday, July 12, 2026, 7:30 AM to 4:15 PM BST
Abstract Title: Automated APOE Genotyping Directly from Blood and Buccal Specimens Without DNA Isolation: A Point-of-Care Ready Approach
Poster Number: 1282
Session Title: Developing Topics: Basic Science and Pathogenesis
Date and Time: Tuesday, July 14, 2026, 7:30 AM to 4:15 PM BST
About Alzheimer's Association International Conference
The AAIC is the world's largest gathering dedicated to advancing dementia science. Each year, AAIC convenes the world’s leading basic scientists, clinical researchers, early-career investigators, clinicians, and the care research community to share groundbreaking research discoveries that will lead to methods of prevention and treatment, and improvements in diagnosis for Alzheimer’s disease and related dementias.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. For more information, please visit the company’s website at www.aptorumgroup.com.
About DiamiR Biosciences
DiamiR Biosciences Corp. is a private molecular diagnostics company focused on developing and commercializing minimally invasive tests offered through its CLIA-certified, CAP-accredited laboratory for early detection and monitoring of brain health conditions and other diseases in clinical trials and clinical practice settings. DiamiR’s proprietary platform technology, protected by over 50 issued patents worldwide, is based on quantitative analysis of organ-enriched, including brain-enriched and inflammation-associated, microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. In addition, DiamiR offers protein and genetic biomarker analyses. DiamiR collaborates with leading academic centers, disease foundations, and biopharma companies. For more information, please visit the company's website at www.diamirbio.com and connect with DiamiR on LinkedIn.
Merger between Aptorum Group and DiamiR Biosciences
As was previously announced on July 16, 2025, Aptorum Group and DiamiR entered into a definitive agreement for an all-stock merger transaction. On June 9, 2026 shareholders of both companies approved the merger. The completion of the merger remains subject to the satisfaction or waiver of the remaining customary closing conditions described in the merger agreement. The companies currently expect the transaction to close before fiscal 2027. Upon closing of the merger, DiamiR will become a wholly-owned subsidiary of Aptorum Group and the combined company will be renamed Niki BioSolutions, Inc., a Delaware corporation.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, statements regarding the consummation and closing of the proposed merger, the satisfactory completion of all conditions to the merger, Aptorum’s and DiamiR’s ability to successfully operate its business and provide value to stockholders after completion of the merger, Aptorum’s and DiamiR’s future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing, future or ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to Aptorum’s and DiamiR’s industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for increasing revenue and executing growth initiatives. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industries in which Aptorum and DiamiR operate may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which Aptorum and DiamiR operate, the financial markets, economic, business and regulatory and other factors, such as Aptorum’s and DiamiR’s ability to execute on their strategies. More detailed information about risk factors can be found in the Aptorum’s Annual Report on Form 20-F under the heading “Risk Factors,” and in other reports filed by the Aptorum, including reports on Form 6-K and the registration statement on Form S-4 (File No. 333-290742) that the SEC declared effective on May 13, 2026. Aptorum and DiamiR do not undertake any duty to update forward-looking statements after the date of this press release.
No Offer or Solicitation
This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any proxy, consent, authorization, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of the U.S. Securities Act of 1933, as amended.
Additional Information About the Proposed Merger and Where to Find It
In connection with the merger, Aptorum filed a current report on Form 6-K to disclose additional details about the merger and a registration statement on Form S-4 with the SEC. Investors and security holders of Aptorum are advised to read the Form S-4, and amendments thereto, because they contain important information about the transaction and the parties to the transaction, and are urged to read the prospectus and the other relevant materials before making any investment decision with respect to the merger. Shareholders can obtain copies of the notice, without charge, at the SEC's website at www.sec.gov or by directing a request to: Ian Huen, telephone: +44 20 80929299.
For more information, please contact:
Aptorum Group Limited
Investor Relations Department
investor.relations@aptorumgroup.com
+44 20 80929299
DiamiR Biosciences
Alidad Mireskandari, PhD
203-570-8275
amireskandari@diamirbio.com
